Tetra Radar · FDA Approvals · Decision date
CNP: FDA decision date
Ascendis Pharma A/S (ASND) · 28 February 2026
As a result of further information from the Company submitted to the FDA on November 5, 2025, related to the post-marketing requirement in response to the FDA’s ongoing review of the NDA, the FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of February 28, 2026 to complete its review.
Source: 6-K of 23 February 2026
The FDA approved it on 27 February 2026.
The FDA approved YUVIWEL to increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses.
Ascendis Pharma A/S on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.